Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-30T01:31:09.084Z Has data issue: false hasContentIssue false
  • English
  • Français

EPA-1713 – Placebo Effect in a Multiple Sclerosis Patient under Tisabri Treatment

Published online by Cambridge University Press:  15 April 2020

A. Benito  and
P. Ruisoto
A. Benito
Affiliation:
Faculty of Psychology, Salamanca University, Salamanca, Spain
P. Ruisoto
Affiliation:
Department of Basic Psychology Psychobiology and Methodology of Behavioral Sciences, University of Salamanca, Salamanca, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Placebo efect has been a controversial and hot topic within psychoneuroinmunology. However recent studies have shed considerable light on the potential mechanisms of placebo responses and their role in health outcomes.

Aim and objectives

The objective of this study is to analyze the effects of a process of classical conditioning on the evolution of the symptoms present in a case of multiple sclerosis.

Method

Case study in a 40 years woman diagnosed with relapsing-remitting multiple sclerosis treated with natalizumab (Tisabri©).

Results

The results support the consideration of multiple sclerosis as a stress-related disorder.

Discussion

The role of expectations of improvement in the treatmente of multiple sclerosis is further discussed.

Type
P25 - Psychoneuroimmunology
Information
European Psychiatry , Volume 29 , Issue S1: Abstracts of the 22nd European Congress of Psychiatry , 2014 , pp. 1
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.